Structural Dynamics-Driven Discovery of Anticancer and Antimetastatic Effects of Diltiazem and Glibenclamide Targeting Urokinase Receptor-Reference-Cited by-同舟云学术

Structural Dynamics-Driven Discovery of Anticancer and Antimetastatic Effects of Diltiazem and Glibenclamide Targeting Urokinase Receptor

Published:2023-02-28 Issue:8 Volume:66 Page:5415-5426
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhou Yang¹²,Song Meiru²³,Xie Daoqing²,Yan Shufeng⁴,Yu Shujuan²,Xie Song²,Cai Meiqin²,Li Hanlin²,Shang Le⁵,Jiang Longguang²^ORCID,Yuan Cai¹^ORCID,Huang Mingdong¹²^ORCID,Li Jinyu²^ORCID,Xu Peng¹⁶^ORCID

Affiliation:

1. College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian 350108, P. R. China

2. College of Chemistry, Fuzhou University, Fuzhou, Fujian 350108, P. R. China

3. Henan Academy of Sciences, Zhengzhou, Henan 450046, P. R. China

4. Sanming University, Sanming, Fujian 365004, P. R. China

5. Fujian Institute of Research on the Structure of Matter, Chinese Academy of Science, Fuzhou, Fujian 350109, P. R. China

6. Fujian Key Laboratory of Marine Enzyme Engineering, Fuzhou University, Fuzhou, Fujian 350108, P. R. China

Funder

Natural Science Foundation of Fujian Province

National Natural Science Foundation of China

Fujian Province

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01663

Reference61 articles.

1. Role of Urokinase Receptor in Tumor Progression and Development

2. Therapeutics targeting the fibrinolytic system

3. Structural Basis for Therapeutic Intervention of uPA/uPAR System

4. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies

5. Cancer therapy targeting the fibrinolytic system

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interface-driven structural evolution on diltiazem as novel uPAR inhibitors: from in silico design to in vitro evaluation;Molecular Diversity;2024-06-27

2. Oral administration of proniosomal glibenclamide formulation protects testicular tissue from hyperglycemia fluctuations and ROS via Nrf2/HO-1 pathway;Heliyon;2024-05

3. In silico screening of natural products as uPAR inhibitors via multiple structure-based docking and molecular dynamics simulations;Journal of Biomolecular Structure and Dynamics;2023-12-18

4. Targeted imaging of uPAR expression in vivo with cyclic AE105 variants;Scientific Reports;2023-10-11